TABLE 1.

Summary of the in vivo activity of AZD1775 and irinotecan as single agents and in combination

Line	Histology	Treatment	EFS (d)	P	EFS T-C	EFS T/C	MinRTV	Response
NB-1643	Neuroblastoma	AZD1775	8.9	P = 0.009	2.6	1.42	1.455	PD1
NB-1643	Neuroblastoma	IR	33.6	P < 0.001	27.3	5.37	0.032	PR
NB-1643	Neuroblastoma	AZD1775 + IR	41.9	P < 0.001	35.6	6.70	0.000	CR
NB-SD	Neuroblastoma	AZD1775	12.2	P = 0.021	2.1	1.21	1.544	PD1
NB-SD	Neuroblastoma	IR	26	P < 0.01	15.9	2.58	0.730	PD2
NB-SD	Neuroblastoma	AZD1775 + IR	31.6	P < 0.01	21.5	3.13	0.532	PD2
NB-Ebc1	Neuroblastoma	AZD1775	7.1	P = 0.257	0.8	1.12	1.997	PD1
NB-Ebc1	Neuroblastoma	IR	20.1	P < 0.001	13.7	3.18	0.232	PR
NB-Ebc1	Neuroblastoma	AZD1775 + IR	22.5	P < 0.001	16.2	3.56	0.091	PR
OS1	Osteosarcoma	AZD1775	12.7	P < 0.001	16.9	1.66	1.063	PD1
OS1	Osteosarcoma	IR	23.5	P < 0.001	14.4	1.57	1.127	PD1
OS1	Osteosarcoma	AZD1775 + IR	40.6	P < 0.001	>37.6	>2.48	0.579	PD2
OS2	Osteosarcoma	AZD1775	42.4	P < 0.001	6.0	1.37	1.403	PD1
OS2	Osteosarcoma	IR	39.9	P < 0.001	6.2	1.38	1.385	PD1
OS2	Osteosarcoma	AZD1775 + IR	>63	P < 0.001	11.2	1.69	0.957	PD1
OS31	Osteosarcoma	AZD1775	21.9	P = 0.327	1.3	1.06	1.765	PD1
OS31	Osteosarcoma	IR	25.3	P < 0.001	4.7	1.23	1.349	PD1
OS31	Osteosarcoma	AZD1775 + IR	44.9	P < 0.001	24.3	2.18	0.789	PD2
OS33	Osteosarcoma	AZD1775	18.1	P < 0.001	5.9	1.49	1.714	PD1
OS33	Osteosarcoma	IR	25.7	P < 0.001	13.6	2.12	1.365	PD2
OS33	Osteosarcoma	AZD1775 + IR	43.4	P < 0.001	31.3	3.58	0.837	PD2
KT-10	Wilms	AZD1775	22.8	P < 0.001	8.8	1.62	1.278	PD1
KT-10	Wilms	IR	51.1	P < 0.001	37.1	3.64	0.149	PR
KT-10	Wilms	AZD1775 + IR	45.4	P < 0.001	31.4	3.23	0.090	PR
KT-11	Wilms	AZD1775	13.1	P = 0.003	2.3	1.21	0.832	PD1
KT-11	Wilms	IR	32.2	P < 0.001	21.3	2.97	0.107	CR
KT-11	Wilms	AZD1775 + IR	40.3	P < 0.001	29.4	3.72	0.050	CR
KT-13	Wilms	AZD1775	12.7	P = 0.055	4.1	1.48	1.356	PD1
KT-13	Wilms	IR	23.5	P < 0.001	14.9	2.71	0.973	PD2
KT-13	Wilms	AZD1775 + IR	40.6	P < 0.001	21.0	4.71	0.311	PR